Saltrim

Administer orally with or without food. For best absorption and to minimize gastrointestinal upset, it can be taken with food. Ensure sufficient fluid intake to prevent crystalluria.

Co-trimoxazole inhibits bacterial folic acid synthesis. Sulfamethoxazole competitively inhibits dihydropteroate synthase, an enzyme involved in converting para-aminobenzoic acid (PABA) to dihydrofolic acid. Trimethoprim inhibits bacterial dihydrofolate reductase, which converts dihydrofolic acid to tetrahydrofolic acid. This dual blockade provides synergistic antibacterial activity.

• Hypersensitivity to sulfamethoxazole or trimethoprim or any component of the formulation
• Severe renal impairment where plasma concentrations cannot be monitored
• Severe hepatic impairment
• Megaloblastic anemia due to folate deficiency
• Porphyria
• Infants under 2 months of age

Store below 30°C, protected from light and moisture. Do not freeze. Keep out of reach of children. After reconstitution, store as directed on the label (e.g., refrigerated).

Symptoms may include nausea, vomiting, diarrhea, anorexia, headache, dizziness, and mental depression. Acute massive overdose can lead to bone marrow depression and megaloblastic anemia. Treatment is supportive, including gastric lavage, forced diuresis, and administration of leucovorin for folate deficiency.

Pregnancy Category D (risk in late pregnancy due to displacement of bilirubin and risk of kernicterus in neonates). Should be avoided in the first trimester if possible, and definitely in the last few weeks of pregnancy. Excreted in breast milk; use with caution or avoid in breastfeeding mothers, especially if infant is jaundiced or G6PD deficient.